Canagliflozin Ups Survival in Type 2 Diabetes With Macroalbuminuria

Share this content:
Canagliflozin vs placebo is associated with increased survival and renal outcomes in patients with type 2 diabetes and macroalbuminuria.
Canagliflozin vs placebo is associated with increased survival and renal outcomes in patients with type 2 diabetes and macroalbuminuria.
The following article is part of conference coverage from Kidney Week 2018 in San Diego hosted by the American Society of Nephrology. Renal & Urology News staff will be reporting live on medical studies conducted by nephrologists and other specialists who are tops in their field in acute kidney injury, chronic kidney disease, dialysis, transplantation, and more. Check back for the latest news from Kidney Week 2018.

SAN DIEGO—Canagliflozin treatment is associated with improved survival and cardiovascular outcomes in patients with type 2 diabetes and macroalbuminuria, according to study findings presented at the American Society of Nephrology's Kidney Week 2018 conference.

The findings are from a study of 760 participants in the CANVAS (Canagliflozin Cardiovascular Assessment Study) Program who had type 2 diabetes, macroalbuminuria (urinary albumin:creatinine ratio [UACR] greater than 300 mg/g), and a history or high risk of cardiovascular disease. At enrollment, the study cohort had a mean age of 64 years, hemoglobin A1c of 8.5%, and estimated glomerular filtration rate (eGFR) of 66 mL/min/1.73 m2 and a median UACR of 722 mg/g. Investigators had randomly assigned patients receive canagliflozin or placebo.

Compared with placebo recipients, canagliflozin-treated patients experienced a 36% decrease in UACR from baseline to the end of follow-up, Vlado Perkovic, MD, of the George Institute for Global Health and the University of New South Wales in Australia, and colleagues reported. The canagliflozin group also had a slower chronic annual decline in eGFR than the placebo group (˗1.76 vs ˗4.77 mL/min/1.73 m2).

In addition, compared with placebo, canagliflozin was associated with a significant 42% decreased risk of a composite outcome of a 40% decrease in eGFR, end-stage renal disease, or renal death, as well as a significant 37% decrease in all-cause mortality.


Visit Renal & Urology News' conference section for continuous coverage from Kidney Week 2018.

Reference

Perkovic V, Li Q, Jardin MJ, et al. Canaglilozin in patients with type 2 diabetes and macroalbuminuria: Data from the CANVAS Program. Data presented at the American Society of Nephrology's 2018 Kidney Week conference in San Diego, Oct. 23-28. Abstract TH-OR039.

You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters